

Special Issue

Drugs from Arthropods: Leveraging Antimicrobial Peptides from Arthropods

Message from the Guest Editor

Dear Colleague, Life-threatening infectious diseases remain among the leading causes of death in the human population worldwide. Multiple outbreaks of epidemic infectious diseases have occurred in the last few decades, including those caused by viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence or re-emergence of such diseases has revealed the deficiency in the pipeline for the discovery and development of anti-infective drugs. One promising solution is the extensive collection of antimicrobial peptides (AMPs), which are valuable because they have evolved for millions of years in multicellular organisms that rely on innate immunity to control and prevent pathogen infection. Arthropods produce the broadest repertoire of AMPs, and their potent antimicrobial, antifungal, antiparasitic, antiviral, and even anticancer, activities in vitro and in vivo have promoted their development as therapeutics. In this Special Issue, we invite you to prepare and submit your manuscripts describing the chemistry of AMPs from arthropods, their biological activities and modes of action, AMP mimetics and related topics.

Guest Editor

Dr. Miray Tonk Rügen

1. Institute for Insect Biotechnology, Department of Applied Entomology, Justus Liebig University, Giessen, Germany
2. LOEWE Centre for Translational Biodiversity Genomics (LOEWE-TBG), Frankfurt, Germany

Deadline for manuscript submissions

closed (15 October 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/88461

Antibiotics

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.3
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(General Pharmacology, Toxicology and Pharmaceutics)